Literature DB >> 31834824

Effects of Toll-Like Receptor 4 Inhibition on Transforming Growth Factor-β2 Signaling in the Human Trabecular Meshwork.

Tasneem P Sharma1, Stacy Curry1, Colleen M McDowell2.   

Abstract

Purpose: Transforming growth factor-β2 (TGFβ2) and Toll-like receptor 4 (TLR4) crosstalk have been implicated in extracellular matrix regulation in the trabecular meshwork (TM) and ocular hypertension in mice. We investigated TLR4 expression in normal and glaucomatous human trabecular meshwork (HTM) sections and utilized a human perfusion organ culture model to determine TGFβ2-TLR4 signaling crosstalk in glaucoma.
Methods: Expression of TLR4 was determined in TM of normal and glaucomatous human eyes. Anterior segments of paired human eyes were perfused at a constant flow rate (2.5 μL/min) for 4 days to acquire stable baseline intraocular pressures (IOPs). We treated paired eyes with two different treatment paradigms: (1) TGFβ2 in one eye and vehicle control in the paired eye, (2) TGFβ2 in one eye and TGFβ2 + TLR4 inhibitor TAK-242 in the paired eye. Perfusate and TM tissue were collected and analyzed for fibronectin (FN) and collagen IV (COLIV) expression.
Results: We observed increased TLR4 expression in glaucomatous HTM sections compared to normal (age-matched) (P < 0.05). Significant elevation of IOP was detected in 47% of TGFβ2-treated anterior segments (P < 0.01) compared to control, and in TGFβ2 treated compared with co-treatment with TGFβ2 + TLR4 inhibitor (P < 0.0001). An increase in FN and COLIV expression was observed after TGFβ2 treatment, and inhibition of TLR4 signaling decreased TGFβ2-induced FN and COLIV expression in perfusate (P < 0.05). Conclusions: These studies identify TGFβ2-TLR4 crosstalk as a novel pathway in glaucoma. They provide a potential new target to lower IOP and explore glaucoma pathogenesis.

Entities:  

Keywords:  IOP; glaucoma; trabecular meshwork

Year:  2019        PMID: 31834824      PMCID: PMC7175615          DOI: 10.1089/jop.2019.0076

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  36 in total

Review 1.  The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors.

Authors:  Taro Kawai; Shizuo Akira
Journal:  Nat Immunol       Date:  2010-04-20       Impact factor: 25.606

Review 2.  Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors.

Authors:  Kensuke Miyake
Journal:  Semin Immunol       Date:  2007-02-01       Impact factor: 11.130

3.  A novel cyclohexene derivative, ethyl (6R)-6-[N-(2-Chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate (TAK-242), selectively inhibits toll-like receptor 4-mediated cytokine production through suppression of intracellular signaling.

Authors:  Masayuki Ii; Naoko Matsunaga; Kaoru Hazeki; Kazuyo Nakamura; Katsunori Takashima; Tsukasa Seya; Osamu Hazeki; Tomoyuki Kitazaki; Yuji Iizawa
Journal:  Mol Pharmacol       Date:  2005-12-22       Impact factor: 4.436

4.  Toll-like receptor 4 signaling augments transforming growth factor-β responses: a novel mechanism for maintaining and amplifying fibrosis in scleroderma.

Authors:  Swati Bhattacharyya; Kathleen Kelley; Denisa S Melichian; Zenshiro Tamaki; Feng Fang; Yunyun Su; Gilbert Feng; Richard M Pope; G R Scott Budinger; Gökhan M Mutlu; Robert Lafyatis; Timothy Radstake; Carol Feghali-Bostwick; John Varga
Journal:  Am J Pathol       Date:  2012-11-07       Impact factor: 4.307

5.  Induction of tissue transglutaminase in the trabecular meshwork by TGF-beta1 and TGF-beta2.

Authors:  U Welge-Lüssen; C A May; E Lütjen-Drecoll
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-07       Impact factor: 4.799

6.  Adenoviral gene transfer of active human transforming growth factor-{beta}2 elevates intraocular pressure and reduces outflow facility in rodent eyes.

Authors:  Allan R Shepard; J Cameron Millar; Iok-Hou Pang; Nasreen Jacobson; Wan-Heng Wang; Abbot F Clark
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-12-03       Impact factor: 4.799

7.  TLR4 enhances TGF-beta signaling and hepatic fibrosis.

Authors:  Ekihiro Seki; Samuele De Minicis; Christoph H Osterreicher; Johannes Kluwe; Yosuke Osawa; David A Brenner; Robert F Schwabe
Journal:  Nat Med       Date:  2007-10-21       Impact factor: 53.440

Review 8.  DAMPening inflammation by modulating TLR signalling.

Authors:  A M Piccinini; K S Midwood
Journal:  Mediators Inflamm       Date:  2010-07-13       Impact factor: 4.711

9.  ABCB1 transporter and Toll-like receptor 4 in trabecular meshwork cells.

Authors:  Algis Grybauskas; Tomoyo Koga; Paulius V Kuprys; Michael Nolan; Ryan McCarty; Loyal Walker; Kelsey A Green; William M Norkett; Beatrice Y J T Yue; Paul A Knepper
Journal:  Mol Vis       Date:  2015-03-05       Impact factor: 2.367

10.  Pharmacological Inhibition of Toll-Like Receptor-4 Signaling by TAK242 Prevents and Induces Regression of Experimental Organ Fibrosis.

Authors:  Swati Bhattacharyya; Wenxia Wang; Zenshiro Tamaki; Bo Shi; Anjana Yeldandi; Yasuhiro Tsukimi; Masashi Yamasaki; John Varga
Journal:  Front Immunol       Date:  2018-10-23       Impact factor: 7.561

View more
  3 in total

1.  Fibronectin extra domain A (FN-EDA) causes glaucomatous trabecular meshwork, retina, and optic nerve damage in mice.

Authors:  Timur A Mavlyutov; Justin J Myrah; Anil K Chauhan; Yang Liu; Colleen M McDowell
Journal:  Cell Biosci       Date:  2022-05-26       Impact factor: 9.584

2.  Fibronectin extra domain A (FN-EDA) elevates intraocular pressure through Toll-like receptor 4 signaling.

Authors:  Amanda L Roberts; Timur A Mavlyutov; Tanisha E Perlmutter; Stacy M Curry; Sherri L Harris; Anil K Chauhan; Colleen M McDowell
Journal:  Sci Rep       Date:  2020-06-17       Impact factor: 4.379

3.  A20 Attenuates the Fibrotic Response in the Trabecular Meshwork.

Authors:  Philip Mzyk; Emma G Zalog; Colleen M McDowell
Journal:  Int J Mol Sci       Date:  2022-02-09       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.